Navigation Links
Dominion Diagnostics -- The Only Specialty Urine Drug Monitoring Laboratory to Offer Quantitative Detection of Tapentadol (Nucynta(TM)) by LC/MS/MS
Date:9/14/2009

NORTH KINGSTOWN, R.I., Sept. 14 /PRNewswire/ -- Dominion Diagnostics (Dominion) has recently developed and validated one of the first clinical quantitative assays for the drug tapentadol (Nucynta(TM)) performed by liquid chromatography/tandem mass spectrometry (LC/MS/MS). Tapentadol, recently approved for use by the FDA, is a centrally-active analgesic that has demonstrated efficacy in pain relief with improved gastrointestinal tolerability compared to other opioids for pain management.

Dominion's new assay by LC/MS/MS can detect and identify the primary drug tapentadol. Tapentadol is extensively metabolized in humans. In clinical studies 97% of the administered dose was metabolized, with 70% of the dose excreted in the urine in the conjugated form (55% as tapentadol-O-glucuronide and 15% and tapentadol-O-sulfate). Tapentadol excretion is almost exclusively renal. In a clinical study, it was shown that greater than 95% of a single dose of tapentadol was excreted in the urine within 24 hours of oral administration(1).

"This is a noteworthy achievement for our Research & Development (R&D) and Laboratory Teams," stated Chief Operating Officer Stephen Jordan. "Dominion has invested considerable time and resources in developing this new tapentadol assay. Providing assays for new pain medications allows us to better support our clients' need for relevant and accurate technologies when relying on urine drug monitoring to support patient adherence."

Dominion's quantitative tapentadol assay, one of the first presented to the industry, is now available to all clients across the country. This new development comes as part of Dominion's continued commitment to unparalleled laboratory excellence. Dominion continues to lead the industry in its quest for accurate, clinically relevant science for use in appropriately monitoring chronic pain patients. Dominion's R&D team actively works with leading assay manufacturers and pharmaceutical companies to develop accurate, specific tests that meet current and future needs of the growing pain management industry.

"Our LC/MS/MS assay for tapentadol is highly sensitive and offers clinicians an accurate means of detecting tapentadol in patients that are prescribed the drug, patients that may be diverting their medications, or in other cases where a patient may have been provided the drug from other sources," Dominion's Director of Research & Development Matthew Woodcock, Ph.D. commented. "At Dominion, we recognize the important clinical implications of urine drug monitoring, and we pride ourselves on offering scientifically accurate solutions to support every clinical scenario."

Source:

(1) Terlinden R et al., Eur J Drug Metab Pharmacokinet (2007); Jul-Sep 32(3): 163-169.

Nucynta(TM) is a registered trademark of Ortho-McNeil(R), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

ABOUT DOMINION DIAGNOSTICS

Dominion Diagnostics is a premier provider of comprehensive clinical quantitative urine drug testing, medication monitoring and support services nationwide. For over 13 years, Dominion has provided services to thousands of clients in a variety of medical specialties, including Pain Medicine, Primary Care, Addiction Treatment, Behavioral Health, Psychiatry and Hospital Systems. Dominion is supported by a world-class team that shares a commitment to clinical and operational excellence. For more information about Dominion, please visit www.dominiondiagnostics.com.

    Contact:
    Julie Lenahan
    Director of Marketing
    Dominion Diagnostics
    (401) 667-0876
    jlenahan@dominiondiagnostics.com


'/>"/>
SOURCE Dominion Diagnostics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Dominion Diagnostics to Host Open House Reception in New Vermont Laboratory Facility
2. Dominion Helps Communities by Donating $1 Million to Health Clinics
3. Capital BlueCross Acquires Dominion Dental
4. Dominion Diagnostics Announces Launch of Comprehensive New Company Website
5. Dominion Diagnostics Supports Rhode Islands Toys for Tots Initiative at Its 2007 Holiday Celebration
6. Quest Diagnostics To Speak at the Bank of America Merrill Lynch Global Healthcare Conference
7. Quest Diagnostics Marks Sixth Year on Dow Jones Sustainability Index
8. Reportlinker Adds Therapeutics and Diagnostics for Womens Disorders Report
9. Frost & Sullivan: Malaysia Diagnostics and Devices Industry Outlook 2009
10. Quest Diagnostics Declares Quarterly Cash Dividend
11. eCardio Diagnostics Expands Corporate Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Prior Lake MN (PRWEB) , ... February 24, ... ... the launch of its newly designed TaskMate Go. Core benefits and advantages built ... grain finish and a stylish, functional look and feel. Ability to gain the ...
(Date:2/24/2017)... ... February 24, 2017 , ... WHAT: , ... and recognition opportunities as well as advocacy for the state and region‘s technology ... February 23. The Council's Innovation Forecast event highlights innovation throughout the region ...
(Date:2/24/2017)... ... ... Smart Machine Age is here, and it’s disrupting everything. Not only could it drive ... United States may be taken over by technology in the next five to fifteen ... colleagues is drawing to a close. Success will belong to those who can quiet ...
(Date:2/24/2017)... ... 2017 , ... Healthcare Associates of McKinney announced today that they ... 8080 State Highway 121, Suite 210, McKinney, Texas 75070. It is in the ... As the practice has grown, the need for more space has been paramount. ...
(Date:2/24/2017)... ... February 24, 2017 , ... The California State University Institute for ... engaged in or interested in palliative care education and research. The Symposium, “Innovate. ... North County San Diego on Sept. 28 and 29, 2017, on the campus of ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb. 23, 2017 Non-alcoholic ... on the various drugs being developed for ... all the drugs that are in various ... The pipeline focuses on novel pharmacologic drugs ... stem cell therapies, recombinant proteins and RNA-based ...
(Date:2/24/2017)... , Feb 24, 2017 ... Committee,s proposal for a new Board of Directors that ... The 2016-2017 Nomination Committee comprises representatives of the company,s ... quarter of 2016 who have accepted a seat on ... The composition of the 2016-2017 Nomination Committee was as ...
(Date:2/24/2017)... Feb 24, 2017 Research and Markets has ... and Strategies - 2016" report to their offering. ... The latest research Urinary ... data and benchmarks in the global Urinary Incontinence market. The ... are the key drugs marketed for Urinary Incontinence and their clinical ...
Breaking Medicine Technology: